VANCOUVER, BC, Feb. 25, 2026  — Equity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines[1]. Five companies positioned at the forefront of this expansion include Oncolytics Biotech (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), CRISPR Therapeutics (NASDAQ:CRSP), BioNTech (NASDAQ:BNTX), and Novocure (NASDAQ:NVCR). The broader […]

NEW YORK, Feb. 25, 2026  — USA News Group News Commentary — Global military spending reached a record $2.72 trillion in 2024, marking the steepest annual increase since the Cold War[1]. The Department of Defense has requested $3.0 billion for hypersonic weapons programs in its FY2026 budget, signaling sustained investment in next-generation strike and defense capabilities[2]. Companies positioned across this […]